U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 2231 - 2240 of 4697 results

Status:
Other

Class (Stereo):
CHEMICAL (ABSOLUTE)



Elaiophylin (also known as Azalomycin-B) is a natural compound, a macrolide antibiotic that was first isolated from a culture of Streptomyces melanosporus. Elaiophylin is a novel and potent inhibitor of late-stage autophagy with outstanding antitumor activity in human ovarian cancer cells. In addition was shown, that elaiophylin could be a promising therapeutic strategy for overcoming incurable multiple myeloma (MM), even when TP53 mutations are present. It is known, that autophagy inhibition is a promising approach and is being investigated as a new target strategy for ovarian cancer treatment. Autophagy, a lysosome-dependent pathway, is a complex catabolic process that involves the degradation of dysfunctional or useless cytoplasmic constituents. Thus, elaiophylin, a novel autophagy inhibitor with unique chemical structure, provides the potential for structure-based development of autophagy inhibitors for new cancer therapies. Also, elaiophylin is an inhibitor of a testosterone 5 alpha-reductase.
Status:
Other

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

3-Hydroxymethyl-beta-carboline (3-HMC) is a benzodiazepine receptor antagonist both in vitro and in vivo. It antagonizes both the anticonvulsant and “anxiolytic” actions of diazepam. 3-HMC decreases sleep and reverses the hypnotic actions of flurazepam. 3-HMC is an active antagonist of the cerebrovascular and cerebral metabolic depression produced by flurazepam and can stimulate cerebral blood flow and cerebral O2 consumption at high doses when given alone. 3-HMC has the ability to specifically antagonize fentanyl anesthesia.
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Showing 2231 - 2240 of 4697 results